Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
| Autor: | Alessandro Massolo, Luca Morelli, Vittoria Raffa, Caterina Vivaldi, Enrico Vasile, Dimitri Giunchi, Gregorio Di Franco, Matteo Palmeri, Luca Pollina, Alfredo Falcone, Margherita Piccardi, Luciana Dente, Niccola Funel, Alice Usai, Perla Cateni |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pancreatic ductal adenocarcinoma medicine.medical_treatment pancreatic cancer Cancer recurrence Article zebrafish avatar Pancreatic cancer Internal medicine medicine Zebrafish preclinical model RC254-282 Therapeutic strategy Chemotherapy biology business.industry Chemosensitivity Personalized medicine Preclinical model Zebrafish avatar Neoplasms. Tumors. Oncology. Including cancer and carcinogens personalized medicine biology.organism_classification medicine.disease chemosensitivity business Adjuvant |
| Zdroj: | Cancers, Vol 13, Iss 4131, p 4131 (2021) Cancers Volume 13 Issue 16 |
| ISSN: | 2072-6694 |
| Popis: | It is increasingly evident the necessity of new predictive tools for the treatment of pancreatic ductal adenocarcinoma in a personalized manner. We present a co-clinical trial testing the predictiveness of zPDX (zebrafish patient-derived xenograft) for assessing if patients could benefit from a therapeutic strategy (ClinicalTrials.gov: XenoZ, NCT03668418). zPDX are generated xenografting tumor tissues in zebrafish embryos. zPDX were exposed to chemotherapy regimens commonly used. We considered a zPDX a responder (R) when a decrease ≥50% in the relative tumor area was reported otherwise, we considered them a non-responder (NR). Patients were classified as Responder if their own zPDX was classified as an R for the chemotherapy scheme she/he received an adjuvant treatment otherwise, we considered them a Non-Responder. We compared the cancer recurrence rate at 1 year after surgery and the disease-free survival (DFS) of patients of both groups. We reported a statistically significant higher recurrence rate in the Non-Responder group: 66.7% vs. 14.3% (p = 0.036), anticipating relapse/no relapse within 1 year after surgery in 12/16 patients. The mean DFS was longer in the R-group than the NR-group, even if not statistically significant: 19.2 months vs. 12.7 months, (p = 0.123). The proposed strategy could potentially improve preclinical evaluation of treatment modalities and may enable prospective therapeutic selection in everyday clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|